Cited by 498Thyroid Disorders and TreatmentsThyroid and Parathyroid SurgeryHormonal and reproductive studies

Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism

Open access
Stott, David J., Rodondi, Nicolas, Kearney, Patricia M., Ford, Ian, Westendorp, Rudi G.J., Mooijaart, Simon P., Sattar, Naveed, Aubert, Carole E. +38 more·2017·New England Journal of Medicine

Abstract

BACKGROUND: The use of levothyroxine to treat subclinical hypothyroidism is controversial. We aimed to determine whether levothyroxine provided clinical benefits in older persons with this condition. METHODS: We conducted a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults who were at least 65 years of age and who had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range). A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment. The two primary outcomes were the change in the Hypothyroid Symptoms score and Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year (range of each scale is 0 to 100, with higher scores indicating more symptoms or tiredness, respectively; minimum clinically important difference, 9 points). RESULTS: The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women. The mean (±SD) thyrotropin level was 6.40±2.01 mIU per liter at baseline; at 1 year, this level had decreased to 5.48 mIU per liter in the placebo group, as compared with 3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 μg. We found no differences in the mean change at 1 year in the Hypothyroid Symptoms score (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group; between-group difference, 0.0; 95% confidence interval [CI], -2.0 to 2.1) or the Tiredness score (3.2±17.7 and 3.8±18.4, respectively; between-group difference, 0.4; 95% CI, -2.1 to 2.9). No beneficial effects of levothyroxine were seen on secondary-outcome measures. There was no significant excess of serious adverse events prespecified as being of special interest. CONCLUSIONS: Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism. (Funded by European Union FP7 and others; TRUST ClinicalTrials.gov number, NCT01660126 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1603825

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Trials do not show a benefit from thyroid hormone replacement in persistent subclinical hypothyroidism.

    “or to those with persistent subclinical hypothyroidism, where trials do not show a benefit from thyroid hormone replacement. 12,15,16,44 -46”

    From Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement (2023) · cites this paper as [15]

    The Participants section (p. 2) confirms that the trial enrolled adults aged 65 or older with persistent subclinical hypothyroidism. The Discussion (p. 10) reports no symptomatic benefit from levothyroxine, but the claim is broader than this trial's population and outcome; the Discussion (p. 9) also says benefit in some subgroups could not be excluded. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • No clear advantages of treating subclinical hypothyroidism in older individuals (>65 years) have been observed in terms of neurocognitive function and quality of life.

    “No clear advantages of treating subclinical hypothyroidism in older individuals (>65 years) have been observed in terms of neurocognitive function and quality of life, 146-148”

    From Hypothyroidism (2024) · cites this paper as [147]

  • Large RCTs have shown no improvement in hypothyroid symptoms or quality of life in older patients with subclinical hypothyroidism during treatment with levothyroxine.

    “large RCTs have shown no improvement in hypothyroid symptoms or quality of life (QoL) in older patients with subclinical hypothyroidism during treatment with levothyroxine. 15 -17”
  • A large placebo-controlled trial among patients with subclinical hypothyroidism at least 65 years of age demonstrated no apparent benefits of LT4 treatment.

    “A large placebo-controlled trial among patients with subclinical hypothyroidism at least 65 years of age demonstrated no apparent benefits of LT4 treatment [51].”
  • The meta-analysis included a significant proportion of elderly participants (mean age > 65 years) with mild TSH elevations which may reflect the aging process rather than intrinsic thyroid disease.

    “However, the meta-analysis included a significant proportion of elderly participants (mean age > 65 years) with mild TSH elevations which may reflect the aging process rather than intrinsic thyroid disease [18, 57].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [5]5. Baumgartner C, den Elzen WP, Blum MR, et al. Variation in treatment strategies of Swiss general practitioners for subclinical hypothyroidism in older adults. Swiss Med Wkly 2015; 145: w14156.
  2. [22]22. evaluation: the Barthel Index. Md State Med J 1965; 14: 61-5.
  3. [24]24. McClure NS, Xie F, Luo N, Johnson JA. Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value Health (in press).

Cited by

Sorted by citations

Authors
Stott, D. J., Rodondi, N., Kearney, P. M., Ford, I., Westendorp, R. G. J., Mooijaart, S. P., Sattar, N., Aubert, C. E., Aujesky, D., Bauer, D. C., Baumgartner, C., Blum, M. R., Browne, J. P., Byrne, S., Collet, T.-H., Dekkers, O. M., den Elzen, W. P. J., Du Puy, R. S., Ellis, G., Feller, M., Floriani, C., Hendry, K., Hurley, C., Jukema, J. W., Kean, S., Kelly, M., Krebs, D., Langhorne, P., McCarthy, G., McCarthy, V., McConnachie, A., McDade, M., Messow, M., O’Flynn, A., O’Riordan, D., Poortvliet, R. K. E., Quinn, T. J., Russell, A., Sinnott, C., Smit, J. W. A., Van Dorland, H. A., Walsh, K. A., Walsh, E. K., Watt, T., Wilson, R., & Gussekloo, J.
Affiliations
University of Bern (CH)
Venue
New England Journal of Medicine
Published
2017-06-29
Volume
376
Issue
26
Pages
2534-2544
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2604882706
Cited by
490
References
25
Citations by year
2026: 42 · 2025: 28 · 2024: 43 · 2023: 47 · 2022: 54 · 2021: 61 · 2020: 62 · 2019: 61 · 2018: 64 · 2017: 27 · 2015: 1
FWCI
46.23
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • SERVAL (Université de Lausanne) (publishedVersion, other-oa)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
  • Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • IRIS (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • BORIS (University Library Bern) (submittedVersion, other-oa)
  • Cork Open Research Archive (University College Cork, Ireland) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo
Funders
  • National Science Foundation
  • Velux Stiftung
  • University of Bern
  • Health Research Board (SPHeRE/2013/1)
  • Inselspital, Universitätsspital Bern
  • European Commission (278148, FP7‐HEALTH‐2011)
  • University of Glasgow
  • University College Cork
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (165409, 320 030-150 025, 150025, 278148, 167826, 320030)
  • Universiteit Leiden
  • Radboud Universiteit
  • Gentofte Hospital
  • Schweizerische Herzstiftung (278148)
  • Leids Universitair Medisch Centrum
  • Rigshospitalet
  • Radboud Universitair Medisch Centrum
  • University of California, San Francisco
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24AR051895)
  • FP7 Health
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
subclinical hypothyroidism, levothyroxine, thyroid hormone replacement, older adults, quality of life, fatigue, thyroid-stimulating hormone, dose adjustment, coronary artery disease, body weight, cost-effectiveness, patient-reported outcomes, health-related quality of life
MeSH terms
Aged, Aged, 80 and over, Double-Blind Method, Fatigue, Female, Humans, Hypothyroidism, Male, Quality of Life, Thyrotropin, Thyroxine, Treatment Failure, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review